Free webinar – Rational EU risk management for oncology medicines
pharmafile | May 4, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | NDA Group, biotech, drugs, pharma, pharmaceutical
It is timely to reflect on how we can best implement the revised GVP module (V) concerning risk management in the interests of patients throughout the life-cycle of a medicine.
Factors to consider include:
- Taking into account the needs of the prescriber and other healthcare professionals
- Applying the resources of the marketing authorisation holder (MAH) effectively to comply with regulatory expectation
- Ensuring risk management plans reflect only measures that MAHs can reasonably control while retaining the MAH’s duty of care
- Remembering risk management during clinical development is intrinsic to Good Clinical Practice
- Providing precise instructions for minimising risk in the protocol and investigator brochure to form the basis of the EU risk management plan
- Designing pivotal studies based on the anticipated target group once marketed
- Defining recommended conditions for safe and effective use of a medicine to minimise risk
Thus, how can we now sensibly apply the revised GVP module for risk management?
This webinar will be conducted by an experienced ex-EU regulator who understands the detail by which a typical RMP will be assessed and who will provide practical guidance to help you produce compliant RMPs effectively and efficiently.
Click here to book your place today. If you require further information, please do not hesitate to contact us.
Our speaker for the event is Dr William Richardson, Medical Advisor at NDA Group.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
